Quture's product demonstrations at three key hospitals have been designed to triangulate the QualOptima analytics value proposition. As the operations company moves from development to marketing and sales, the analysis of the ROI potential of the product is at completion from all three sites. Each project provides unique elements for ROI, so that the insight from each converges to attract additional reference hospitals to license QualOptima.
The clinical trial at the University of Miami Miller School of Medicine and Jackson Memorial Hospital (UoM) focused on measuring clinical performance and outcomes. Dr. Keith Candiotti designed the project to demonstrate the value of the product design to ultimately calculate unreimbursed cost relationships with compliance to evidence-based perioperative protocols. The project measures the impact of performance of evidence-based protocols on outcomes and costs. There are significant costs associated with extended stays and complications in recovery and beyond for well-established practice guidelines from professional organizations, that for the first time connect clinical quality with outcomes and costs. Electronic data capture, aggregation into a second generation database, and imposition of quality and value analytics is essential for hospitals that urgently need to move to value-based purchasing and to comply with accreditation standards. Quture is now further exploring the QualOptima database for patient-centered, personalized medicine applications with Dr. Candiotti.
At Niagara Falls Memorial Medical Center (NFMCC), Quture implemented an evidence-based optimal clinical process for prevention of catheter-acquired urinary tract infections (CAUTI) in the intensive care unit. The ROI analysis announced for completion before September is focused on payment initiatives. The clinical demonstration was selected because it is one of the hospital-acquired conditions (HAC) for which providers are no longer reimbursed and is the major patient safety initiative for 2012. Performance measurement based on a nursing-sensitive protocol augments physician performance at the University of Miami for true interdisciplinary performance measurement.
Springhill Medical Center, Springhill, LA (SMC) is focused on replacing Quture's former peer review product with QualOptima. The ROI evaluation there is based on replacing labor-intensive manual processes with electronic data capture and analytics, while integrating their peer review and performance measurement processes. Successful implementation of a license to the InterSystems product platform for QualOptima is scheduled for completion in early September. The demonstration requires completion of the product as a cloud application. This will demonstrate the market for QualOptima to small and rural medical centers such as SMC. As an established customer of the former peer review product, it was urgent to supplement peer review process with performance measurement, both for compliance with accreditation standards and to prepare for the new fee-for-value payment system.
"The recent Black Book Rankings hospital survey cited in our last press release was extraordinarily significant, stating that 84% of provider organizations without clinical analytics systems in place currently plan to acquire at least one new or additional clinical analytic tools within 12 months," said Feazell. "We have committed over six years and millions of dollars and other resources to create QualOptima. The InterSystems platform powers our product as a breakthrough application of their unparalleled technology. Senior management teams find themselves in charge, but not in control in hospitals throughout America. The survey report indicts that only 16 percent of U.S. hospitals acknowledge they currently have the clinical decision support tools to effectively manage the data needs of the accountable care evolution. Hospital boards and senior management need to prepare their organization for clinical analytics not only in the new payment system, but also for the future of improving care as patients become more involved in their care. Adding personalized medicine and wellness to the business case for QualOptima is a rapidly evolving product strategy and marketing and sales advantage. As delivery systems and payment systems are changing and patient involvement in their care increases, QualOptima empowers data-driven decisions for results-driven success©."
ABOUT QUTURE INTERNATIONAL, INC. (www.quture.com)
Quture International, Inc. is an emerging growth company positioned to become the leading clinical knowledge company in the world. The core competence of Quture is clinical performance enhancement to achieve optimal patient outcomes. Quture's brand is centered on the value proposition of trust, transparency and independence. As the free enterprise solution to improving health and health care while reducing costs, Quture is comprised of a subsidiaries in North America and Europe for the operations of its software technology solutions, plans for a "beyond data" consulting and knowledge applications company, as well as plans for a personalized, proactive, and predictive medicine company with a virtual community of members. These subsidiaries will all be affiliated with the Qx Medical Exchange, which the Company intends to become the largest medical and health exchange in the world. Quture International is a Nevada corporation currently trading under the symbol TCLN.
This release contains forward-looking statements, including, without limitation, statements concerning our business and possible or assumed future results of operations. Our actual results could differ materially from those anticipated in the forward-looking statements for many reasons including: our ability to continue as a going concern, adverse economic changes affecting markets we serve; competition in our markets and industry segments; our timing and the profitability of entering new markets; greater than expected costs, customer acceptance of our products or difficulties related to our integration of the businesses we may acquire; and other risks and uncertainties as may be detailed from time to time in our public announcements and SEC filings. Although we believe the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and our future results, levels of activity, performance or achievements may not meet these expectations. We do not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in our expectations, except as required by law. There is no assurance that a definitive agreement will be completed.
For Further Information Contact:
Constellation Asset Advisors, Inc.
+1 (415) 524-8500
Director of Communications
Most Popular Stories
- Updates on Everglades' Stranded Pilot Whales
- NSA Tracks 5 Billion Cellphone Records a Day
- Hezbollah Chief's Assassination Claimed by Sunni Group
- Stolen Cobalt-60 Recovered in Mexico
- Wind Power and Wildlife Can Coexist
- Ford Mustang Still Packs Power
- Allstate Seeks to Invest in Minority Firms
- Sarmiento to Handle Greeley Latin Ops
- Roybal-Allard Tours Gordon Brush Plant
- First-time Jobless Claims Drop Below 300,000